[ad_1]
The recent boom in the popularity of weight loss drugs such as ozapics, collectively called GLP -1S, has renewed scientific interest in understanding how our body controls the development of muscles. In a recent study, scientists have linked the protein BCL6 with the maintenance of muscle mass and further suggested that BCL6-boosting theraputics may help GLP-1 users to maintain muscles while losing fat.
Similar treatments can also be used to treat other population for muscle damage, such as chronic adults and patients with systemic diseases such as sepsis or cancer.
New study provides major protein to maintain muscle
A new study by the Salk Institute has shown that a protein called BCL6 is important to maintain healthy muscles. The experiments showed that the bottom -level mice of the BCL6 had significantly reduced muscles and power, but the increase in BCL6 successfully reversed those damage.
Results suggest that connecting GLP-1 drugs with BCL6-boosting medicine can help combat unwanted muscle damage. Similar treatments can also be used to treat other population for muscle damage, such as chronic adults and patients with systemic diseases such as sepsis or cancer.
Conclusions were published on January 22, 2025 in the proceedings of the National Academy of Sciences. “The muscle is the most abundant tissue in the human body, so its maintenance is important for our health and quality of life,” Ronald Evans, Professor says and the director of the gene expression laboratory in Salk.
Possible treatment for muscle damage
“Our study shows how our body coordinates the maintenance of all this muscles with our nutrition and energy levels, and with this new insight, we as a side effect of weight loss, age, or disease Can develop medical intervention for patients losing muscles. ” Ronald said.
Through a series of later experiments, many results were obtained. According to the study by the Salk Institute, fasting growth promotes the secretion of hormones, which reduces the levels of BCL6 in muscle cells. BCL6 is a regulator of SOCS2, so low BCL6 leads to low SOCS2.
At normal levels, BCL6 controls how much SOCS2 is expressed and therefore, how much IGF1 is produced. In animals without BCL6, the lack of control over SOCS2 slowed down the IGF1 production that the muscles became weak and smaller.
[ad_2]
